Not Yet Recruiting
A First-in-Human Study to Assess Single and Multiple Doses of BMS-986209 in Healthy Participants - CV017-003
Updated: 5 November, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Not Yet Recruiting
Treatment Options
Inclusion Criteria: - Signed informed consent form - Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive. (BMI = weight (kg)/height[m])2. - Normal renal function at screening. - Female participants not of child-bearing potential. - Males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception: to use a condom during the intervention period and for at least 92 days after the last dose of study intervention. Azoospermic males are exempt from contraceptive requirements. - Males with a pregnant or breastfeeing partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of such intercourse, during the intervention period and for at least 92 days after the last dose of study intervention. - Male participants must refrain from donating sperm during the intervention period and for at least 92 days after the last dose of study intervention. Exclusion Criteria: - Women who are of childbearing potential. - Women who are breastfeeding. - Any acute or chronic medical illness. - History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for a 1-week duration in the last month prior to study treatment administration). - History of heart disease or conduction disorders. - Head injury in the last 2 years, intracranial tumor, or aneurysm. - Current or history of rectal bleeding, hematemesis, or hematuria. - Known abdominal aneurysm. - History of gastroesophageal reflux disease, inflammatory bowel disease or any gastrointestinal disease that could impact the absorption of study treatment. - History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding, such as epistaxis. - Personal or family history of hemophilia, Rosenthal syndrome, FXIa deficiency, or other coagulopathies. - History of systemic lupus erythematosus or any other autoimmune diseases. - Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study. - Donation of blood to a blood bank or in a clinical study (except a screening visit or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only). - Current or any history of blood transfusion. - Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study treatment administration). - Current or history of drug or alcohol abuse. Other protocol-defined inclusion/exclusion criteria may apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information